(Q43895313)

27 November 2017

0 references

Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? (English)

1 reference

27 November 2017

0 references

0 references

Bridget Haire

2

0 references

Gregory J Dore

10

object named as

Gregory J Dore

1 reference

27 November 2017

1

Jason Grebely

1 reference

27 November 2017

Lynn E Taylor

3

1 reference

27 November 2017

Paul Macneill

4

1 reference

27 November 2017

Alain H Litwin

5

1 reference

27 November 2017

Tracy Swan

6

1 reference

27 November 2017

Jude Byrne

7

1 reference

27 November 2017

Jules Levin

8

1 reference

27 November 2017

Philip Bruggmann

9

1 reference

27 November 2017

International Network for Hepatitis in Substance Users

11

1 reference

27 November 2017

publication date

4 August 2015

1 reference

27 November 2017

published in

Journal of Hepatology

1 reference

27 November 2017

volume

63

1 reference

27 November 2017

issue

4

1 reference

27 November 2017

page(s)

779-782

1 reference

Recommendations for the management of hepatitis C virus infection among people who inject drugs

27 November 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Epidemiology and natural history of HCV infection.

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

What is killing people with hepatitis C virus infection?

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

People who use drugs, HIV, and human rights

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study.

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Hepatitis C treatment for injection drug users: a review of the available evidence

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Treating viral hepatitis C: efficacy, side effects, and complications

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Alcohol use and treatment of hepatitis C virus: results of a national multicenter study

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Justice, health, and healthcare

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Health-care rationing: critical features, ordinary language, and meaning

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Rationing by Any Other Name

3 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6132058

Sticker shock and the price of new therapies for hepatitis C: is it worth it?

1 December 2018

1 reference

12 December 2020

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

12 December 2020

Bentham in a box: technology assessment and health care allocation

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

12 December 2020

10.1016/J.JHEP.2015.06.014

Identifiers

DOI

1 reference

27 November 2017

0 references

1 reference